Now Also Consulting in Central London & Glasgow
Now Also Consulting in Central London & Glasgow
Now Also Consulting in Central London & Glasgow

Gc group specific protein Macrophage Activating Factor (GcMAF): Immuno-modulating properties in Health

This type of glycoprotein is naturally found in the human body; it has received extensive interest by the scientific community, since some original clinical research was published by Dr Nobuto Yamamoto, a Japanese doctor, in 1990s.

Several studies have been published since, supporting the view that this protein has the capacity to improve a person’s immune response to inflammation, by raising the performance of macrophages (Grk. “big-eaters”), cells known as destroyers of various ‘invaders’ and initiating T-cell response in the immune system, e.g. in allergies and various so-called “autoimmune” disorders.

Some authorities have been critical, raising questions about methodological flaws in some studies, most of the studies have involved small numbers of patients – more research is needed.

The presence of this protein in nature has little financial attraction for the pharmaceutical industry, mainstream Medicine is mostly focused on the use of medications to combat disease.

The use of GcMAF is not approved by FDA in the USA or MHRA in England – its use is described as “unlicensed” and hence “experimental”. It requires fully informed consent, although there have been no serious safety concerns from its use.

GcMAF has the potential for several clinical applications – these include cancer, chronic fatigue, asthma and other forms of chronic inflammation and so-called “autoimmune” disorders.

There are very few manufacturers, who produce reliable GcMAF (oral and injectable).

Please carry out your own research, along with the information you have received from The Burghwood Clinic.

Disclaimer: GcMAF is prescribed to help improve a person’s immune system and quality of life, not to reverse any specific diagnosis, condition or disease; it is not used to replace any conventional therapy such as medications used in oncology, paediatric or psychiatric professional care.

References of GcMAF Immunotherapy

[1] Inui, T., Makita, K., Miura, H., Matsuda, A., Kuchiike, D., Kubo, K., ... & Sakamoto, N. (2014). Case report: a breast cancer patient treated with GcMAF, sonodynamic therapy and hormone therapy. Anticancer research, 34(8), 4589-4593.

[2] Saburi, E., Tavakol-Afshari, J., Biglari, S., & Mortazavi, Y. (2017). Is α-N-acetylgalactosaminidase the key to curing cancer? A mini-review and hypothesis. J BUON, 22(6), 1372-1377.

[3] Thyer, L., Ward, E., Smith, R., Branca, J. J., Morucci, G., Gulisano, M., ... & Pacini, S. (2013). GC protein-derived macrophage-activating factor decreases α-N-acetylgalactosaminidase levels in advanced cancer patients. Oncoimmunology, 2(8), e25769.

[4] Eric Matamoros, M. (2017). GcMAF: a polemic or a highly promising molecule?. World Scientific News, 65, 20-36.

[5] Saburi, E., Saburi, A., & Ghanei, M. (2017). Promising role for Gc-MAF in cancer immunotherapy: from bench to bedside. Caspian Journal of Internal Medicine, 8(4), 228.

[6] Albracht, S. P. (2022). Immunotherapy with GcMAF revisited-A critical overview of the research of Nobuto Yamamoto. Cancer Treatment and Research Communications, 100537.

[7] Yamamoto, N., Ngwenya, B. Z., Sery, T. W., & Pieringer, R. A. (1987). Activation of macrophages by ether analogues of lysophospholipids. Cancer Immunology, Immunotherapy, 25(3), 185-192.

[8] Yamamoto, N. (1996). Structural definition of a potent macrophage activating factor derived from vitamin D3-binding protein with adjuvant activity for antibody production. Molecular immunology, 33(15), 1157-1164.

[9] Yamamoto, N., & Naraparaju, V. R. (1998). Structurally well defined macrophage activating factor derived from vitamin D3 binding protein has a potent adjuvant activity for immunization. Immunology and cell biology, 76(3), 237-244.

[10] Yamamoto, N., & Naraparaju, V. R. (1997). Immunotherapy of BALB/c mice bearing Ehrlich ascites tumour with vitamin D-binding protein-derived macrophage activating factor. Cancer research, 57(11), 2187-2192.

[11] Yamamoto, N., Suyama, H., & Yamamoto, N. (2008). Immunotherapy for prostate cancer with Gc protein-derived macrophage-activating factor, GcMAF. Translational oncology, 1(2), 65-72.

[12] Yamamoto, N., Suyama, H., Nakazato, H., Yamamoto, N., & Koga, Y. (2008). Retracted article: Immunotherapy of metastatic colorectal cancer with vitamin D-binding protein-derived macrophage-activating factor, GcMAF. Cancer Immunology, Immunotherapy, 57(7), 1007-1016.

[13] Yamamoto, N., Suyama, H., Yamamoto, N., & Ushijima, N. (2008). Retracted article: Immunotherapy of metastatic breast cancer patients with vitamin D binding protein derived macrophage activating factor (GcMAF). International journal of cancer, 122(2), 461-467.

[14] Yamamoto, N., Ushijima, N., & Koga, Y. (2009). Retracted article: Immunotherapy of HIV infected patients with Gc protein derived macrophage activating factor (GcMAF). Journal of medical virology, 81(1), 16-26.

[15] Ugarte, A., Bouche, G., & Meheus, L. (2014). Inconsistencies and questionable reliability of the publication “Immunotherapy of metastatic colorectal cancer with vitamin D-binding protein-derived macrophages-activating, GcMAF” by Yamamoto et al. Cancer Immunology, Immunotherapy, 63(12), 1347-1348.

[16] Arney, K., (2008). “Cancer cured for good?” – Gc-MAF and the miracle cure. Cancer Research UK, [Updated 10/05/15].

Contact us if you have further questions or to make an appointment for a consultation.